Clinical trials
Completed Diabetes Mellitus, Type 2 trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
604 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 8 |
| 2002 | 7 |
| 2003 | 14 |
| 2004 | 18 |
| 2005 | 20 |
| 2006 | 33 |
| 2007 | 32 |
| 2008 | 46 |
| 2009 | 50 |
| 2010 | 49 |
| 2011 | 42 |
| 2012 | 37 |
| 2013 | 33 |
| 2014 | 24 |
| 2015 | 26 |
| 2016 | 24 |
| 2017 | 22 |
| 2018 | 16 |
| 2019 | 20 |
| 2020 | 24 |
| 2021 | 15 |
| 2022 | 12 |
| 2023 | 11 |
| 2024 | 12 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 604 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 137 |
| Eli Lilly and Company | 50 |
| Boehringer Ingelheim | 47 |
| AstraZeneca | 41 |
| Sanofi | 39 |
| Hoffmann-La Roche | 26 |
| Novartis Pharmaceuticals | 25 |
| GlaxoSmithKline | 19 |
| Novartis | 15 |
| Takeda | 14 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 604 |
| Diabetes Mellitus | 165 |
| Diabetes Mellitus, Type 1 | 31 |
| Obesity | 22 |
| Insulin Resistance | 18 |
| Glucose Metabolism Disorders | 15 |
| Cardiovascular Diseases | 12 |
| Dyslipidemias | 12 |
| Renal Insufficiency, Chronic | 11 |
| Diabetic Nephropathies | 9 |
Trials
Showing 1 to 25 of 604. Each trial links to its page on Pharma Observatory.
504 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.